IVIG Therapy for Inflammatory Myopathies

Medical Necessity and Standard of Care

• The American College of Rheumatology recommends IVIG for patients with inflammatory myopathies who have severe disease or inadequate response to first-line treatments, with high-quality evidence supporting its efficacy and safety 1, 3
• IVIG is considered standard of care for inflammatory myopathies, with a dosing regimen of 2 gm/kg IV divided over 2-3 days every 28 days, representing a well-established treatment protocol 1, 2, 3

Dosing and Administration

• The prescribed regimen of 2 gm/kg IV divided over 2-3 days every 28 days is aligned with guideline recommendations from the American College of Rheumatology, with a total dose based on ideal body weight 1, 4
• Administration schedule typically involves dividing the dose over 2 consecutive days, with alternative schedules for high doses or patients with cardiac dysfunction 1, 2, 3

Safety Considerations

• Pre-treatment screening is mandatory, including checking serum IgA levels to avoid severe anaphylaxis in patients with IgA deficiency, as recommended by the American Academy of Allergy, Asthma, and Immunology 1, 2, 3
• Cardiac assessment is required before each infusion, with evaluation of cardiac function and fluid status, and consideration of dividing the dose for patients with cardiac dysfunction, according to the American Heart Association 4

Treatment Duration and Monitoring

• Ongoing assessment requirements include monitoring CK levels regularly and performing muscle strength examinations at each follow-up visit, with consideration of alternative or additional immunosuppression if no improvement is seen by 12 weeks, as recommended by the American College of Rheumatology 2, 3
• Once a complete clinical response is achieved, the dosing interval may be lengthened, with ongoing monitoring to adjust treatment as needed 3